MedWatch

Novo Nordisk plans to test cholesterol-lowering oral solution in phase II trial

In a new phase II trial, Novo Nordisk plans to test the company's cholesterol-lowering PCSK9i inhibitor. As a different feature from the phase I trial, the drug will be tested as an oral treatment.

Photo: Tidsvilde Stine/Ritzau Scanpix

This month, Novo Nordisk has initiated a phase II trial with the firm's cholesterol-lowering PCSK9i inhibitor, according to the Danish pharmaceutical firm's Q2 report, published on Wednesday afternoon.

In contrast to the phase I trial, Novo Nordisk will now be testing the peptide-based drug as an oral solution using the same technology that the pharmaceutical company is using for its popular diabetes candidate Rybelsus.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs